U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

Selective Induction of Apoptosis Through the FADD/Caspase-8 Pathway by a p53 C-Terminal Peptide in Human Pre-Malignant and Malignant Cells



Details

  • Personal Author:
  • Description:
    A p53 C-terminal peptide (aa 361-382, p53p), fused at its C-terminus to the minimal carrier peptide of antennapedia (17 aa, Ant; p53p-Ant), induced rapid apoptosis in human cancer cells, via activation of the Fas pathway. We examined p53p-Ant mechanism of action, toxicity in various human normal, non-malignant, pre-malignant and malignant cancer cells and investigated its biophysical characteristics. p53p-Ant selectively induced cell death in only pre-malignant or malignant cells in a p53-dependent manner and was not toxic to normal and non-malignant cells. p53p-Ant was more toxic to the mutant p53 than wild-type p53 phenotype in H1299 lung cancer cells stably expressing human temperature-sensitive p53 mutant 143Ala. Surface plasmon resonance (BIACORE) analysis demonstrated that this peptide had higher binding affinity to mutant p53 as compared to wild-type p53. p53p-Ant induced-cell death had the classical morphological characteristics of apoptosis and had no features of necrosis. The mechanism of cell death by p53p-Ant was through the FADD/caspase-8-dependent pathway without the involvement of the TRAIL pathway, Bcl-2 family and cell cycle changes. Blocking Fas with antibody did not alter the peptide's effect, suggesting that Fas itself did not interact with the peptide. Transfection with a dominant-negative FADD with a deleted N-terminus inhibited p53p-Ant-induced apoptosis. Its mechanism of action is related to the FADD-induced pathway without restoration of other p53 functions. p53p-Ant is a novel anticancer agent with unique selectivity for human cancer cells and could be useful as a prototype for the development of new anti-cancer agents. [Description provided by NIOSH]
  • Subjects:
  • Keywords:
  • ISSN:
    0020-7136
  • Document Type:
  • Funding:
  • Genre:
  • Place as Subject:
  • CIO:
  • Topic:
  • Location:
  • Pages in Document:
    55-64
  • Volume:
    115
  • Issue:
    1
  • NIOSHTIC Number:
    nn:20028853
  • Citation:
    Int J Cancer 2005 May; 115(1):55-64
  • Contact Point Address:
    Robert L. Fine, College of Physicians and Surgeons, Columbia University Medical Center, 650 West 168th Street, BB 20-05, New York, NY 10032
  • Email:
    rlf20@columbia.edu
  • Federal Fiscal Year:
    2005
  • NORA Priority Area:
  • Performing Organization:
    Columbia University Health Sciences
  • Peer Reviewed:
    True
  • Start Date:
    20020601
  • Source Full Name:
    International Journal of Cancer
  • End Date:
    20110630
  • Collection(s):
  • Main Document Checksum:
    urn:sha-512:c4d2d78b8f9e531573b3827647942fef2f8c382cbd41e96e868bb8f3bbd9e1cefabb71001b5a924f8ca8066818406137926beea4754e90d54a00219676531762
  • Download URL:
  • File Type:
    Filetype[PDF - 512.21 KB ]
ON THIS PAGE

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.